Diffuse large B-cell lymphoma refractory
Information
- Disease name
- Diffuse large B-cell lymphoma refractory
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04703686 | Active, not recruiting | Phase 2 | Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy | March 30, 2021 | March 1, 2026 |
| NCT01805557 | Completed | Phase 2/Phase 3 | Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Eligible to Transplantation. BR-DHAP Versus R-DHAP. | February 4, 2013 | November 20, 2020 |
| NCT03589469 | Completed | Phase 2 | Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | August 1, 2018 | August 9, 2022 |
| NCT06271057 | Not yet recruiting | Phase 2 | Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse | April 22, 2024 | October 20, 2027 |
| NCT02594163 | Terminated | Phase 2 | Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell Lymphoma | October 2015 | September 2017 |
| NCT03367143 | Unknown status | Phase 2 | Lenalidomide Plus ICE in the Treatment of Refractory and Relapsed DLBCL | December 2016 | December 2020 |